Co-Diagnostics Statistics

Total Valuation

Co-Diagnostics has a market cap or net worth of GBP 3.89 million. The enterprise value is -3.43 million.

Market Cap	3.89M
Enterprise Value	-3.43M

Important Dates

The next estimated earnings date is Thursday, March 19, 2026.

Earnings Date	Mar 19, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	2.26M
Shares Outstanding	n/a
Shares Change (YoY)	+11.72%
Shares Change (QoQ)	+14.45%
Owned by Insiders (%)	4.57%
Owned by Institutions (%)	11.32%
Float	2.15M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	10.30
PB Ratio	0.13
P/TBV Ratio	0.38
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	0.14
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	0.14

Financial Position

The company has a current ratio of 3.81, with a Debt / Equity ratio of 0.04.

Current Ratio	3.81
Quick Ratio	3.36
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	-0.05
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -62.12% and return on invested capital (ROIC) is -119.76%.

Return on Equity (ROE)	-62.12%
Return on Assets (ROA)	-37.92%
Return on Invested Capital (ROIC)	-119.76%
Return on Capital Employed (ROCE)	-86.56%
Weighted Average Cost of Capital (WACC)	8.72%
Revenue Per Employee	2,862
Profits Per Employee	-181,371
Employee Count	132
Asset Turnover	0.01
Inventory Turnover	0.28

Taxes

Income Tax	-855,856
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -88.68% in the last 52 weeks. The beta is 1.26, so Co-Diagnostics's price volatility has been higher than the market average.

Beta (5Y)	1.26
52-Week Price Change	-88.68%
50-Day Moving Average	6.23
200-Day Moving Average	9.04
Relative Strength Index (RSI)	26.59
Average Volume (20 Days)	2,844

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	0.22

Income Statement

In the last 12 months, Co-Diagnostics had revenue of GBP 377,841 and -23.94 million in losses. Loss per share was -21.58.

Revenue	377,841
Gross Profit	128,585
Operating Income	-26.43M
Pretax Income	-24.80M
Net Income	-23.94M
EBITDA	-25.54M
EBIT	-26.43M
Loss Per Share	-21.58

Full Income Statement

Balance Sheet

The company has 8.51 million in cash and 1.10 million in debt, with a net cash position of 7.42 million.

Cash & Cash Equivalents	8.51M
Total Debt	1.10M
Net Cash	7.42M
Net Cash Per Share	n/a
Equity (Book Value)	29.63M
Book Value Per Share	18.46
Working Capital	7.71M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -23.19 million and capital expenditures -476,914, giving a free cash flow of -23.66 million.

Operating Cash Flow	-23.19M
Capital Expenditures	-476,914
Free Cash Flow	-23.66M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	34.03%
Operating Margin	-6,995.70%
Pretax Margin	-6,562.78%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Co-Diagnostics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-11.72%
Shareholder Yield	-11.72%
Earnings Yield	-615.08%
FCF Yield	-607.98%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on January 2, 2026. It was a reverse split with a ratio of 0.0333333333.

Last Split Date	Jan 2, 2026
Split Type	Reverse
Split Ratio	0.0333333333

Scores

Co-Diagnostics has an Altman Z-Score of -1.69 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.69
Piotroski F-Score	1